7.87 USD
-0.07 (-0.88%)
7.87 USD
0 (0%)
CDXC gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. While CDXC has a great health rating, its profitability is only average at the moment. CDXC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
CDXC had positive earnings in the past year.
In the past year CDXC had a positive cash flow from operations.
In the past 5 years CDXC reported 4 times negative net income.
In multiple years CDXC reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 12.52%, CDXC belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
The Return On Equity of CDXC (18.55%) is better than 90.91% of its industry peers.
CDXC's Return On Invested Capital of 12.13% is amongst the best of the industry. CDXC outperforms 89.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| ROIC | 12.13% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of CDXC (8.58%) is better than 74.55% of its industry peers.
With a decent Operating Margin value of 7.76%, CDXC is doing good in the industry, outperforming 63.64% of the companies in the same industry.
CDXC's Gross Margin of 61.84% is amongst the best of the industry. CDXC outperforms 87.27% of its industry peers.
In the last couple of years the Gross Margin of CDXC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.76% | ||
| PM (TTM) | 8.58% | ||
| GM | 61.84% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CDXC is still creating some value.
CDXC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CDXC has more shares outstanding
Compared to 1 year ago, CDXC has an improved debt to assets ratio.
2.2 Solvency
CDXC has an Altman-Z score of 15.46. This indicates that CDXC is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 15.46, CDXC belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
There is no outstanding debt for CDXC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.46 |
ROIC/WACC1.11
WACC10.97%
2.3 Liquidity
A Current Ratio of 3.57 indicates that CDXC has no problem at all paying its short term obligations.
The Current ratio of CDXC (3.57) is comparable to the rest of the industry.
A Quick Ratio of 3.06 indicates that CDXC has no problem at all paying its short term obligations.
With a Quick ratio value of 3.06, CDXC perfoms like the industry average, outperforming 58.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 242.86% over the past year.
The Revenue has grown by 19.17% in the past year. This is quite good.
CDXC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.56% yearly.
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
3.2 Future
The Earnings Per Share is expected to grow by 43.55% on average over the next years. This is a very strong growth
CDXC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.24% yearly.
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CDXC is valuated quite expensively with a Price/Earnings ratio of 78.70.
The rest of the industry has a similar Price/Earnings ratio as CDXC.
Compared to an average S&P500 Price/Earnings ratio of 26.92, CDXC is valued quite expensively.
With a Price/Forward Earnings ratio of 66.13, CDXC can be considered very expensive at the moment.
The rest of the industry has a similar Price/Forward Earnings ratio as CDXC.
The average S&P500 Price/Forward Earnings ratio is at 23.46. CDXC is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.7 | ||
| Fwd PE | 66.13 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CDXC is valued a bit cheaper than the industry average as 61.82% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CDXC indicates a somewhat cheap valuation: CDXC is cheaper than 65.45% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 51.22 | ||
| EV/EBITDA | 66.44 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of CDXC may justify a higher PE ratio.
CDXC's earnings are expected to grow with 43.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.14
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y43.55%
5. Dividend
5.1 Amount
No dividends for CDXC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.87
-0.07 (-0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners30.29%
Inst Owner Change8.82%
Ins Owners0.01%
Ins Owner Change0%
Market Cap611.89M
Revenue(TTM)99.60M
Net Income(TTM)8.55M
Analysts84.44
Price Target9.21 (17.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)415%
Min EPS beat(2)341.18%
Max EPS beat(2)488.82%
EPS beat(4)4
Avg EPS beat(4)242.8%
Min EPS beat(4)41.19%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)150.17%
EPS beat(12)10
Avg EPS beat(12)102.99%
EPS beat(16)12
Avg EPS beat(16)74.16%
Revenue beat(2)2
Avg Revenue beat(2)6.44%
Min Revenue beat(2)6.07%
Max Revenue beat(2)6.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)6.81%
Revenue beat(8)4
Avg Revenue beat(8)1.29%
Revenue beat(12)4
Avg Revenue beat(12)-1.38%
Revenue beat(16)5
Avg Revenue beat(16)-2.29%
PT rev (1m)17.21%
PT rev (3m)17.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.77%
EPS NY rev (3m)-2.77%
Revenue NQ rev (1m)-1.81%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.7 | ||
| Fwd PE | 66.13 | ||
| P/S | 6.14 | ||
| P/FCF | 51.22 | ||
| P/OCF | 50.53 | ||
| P/B | 13.27 | ||
| P/tB | 13.38 | ||
| EV/EBITDA | 66.44 |
EPS(TTM)0.1
EY1.27%
EPS(NY)0.12
Fwd EY1.51%
FCF(TTM)0.15
FCFY1.95%
OCF(TTM)0.16
OCFY1.98%
SpS1.28
BVpS0.59
TBVpS0.59
PEG (NY)4.14
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| ROCE | 15.35% | ||
| ROIC | 12.13% | ||
| ROICexc | 104.84% | ||
| ROICexgc | 111.73% | ||
| OM | 7.76% | ||
| PM (TTM) | 8.58% | ||
| GM | 61.84% | ||
| FCFM | 11.99% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 20.02% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 7726 | ||
| Cash Conversion | 141.79% | ||
| Profit Quality | 139.72% | ||
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.06 | ||
| Altman-Z | 15.46 |
F-Score7
WACC10.97%
ROIC/WACC1.11
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
EBIT growth 1Y237.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year538.3%
EBIT Next 3Y140.93%
EBIT Next 5YN/A
FCF growth 1Y71.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.14%
OCF growth 3YN/A
OCF growth 5YN/A
CHROMADEX CORP / CDXC FAQ
What is the fundamental rating for CDXC stock?
ChartMill assigns a fundamental rating of 6 / 10 to CDXC.
What is the valuation status for CDXC stock?
ChartMill assigns a valuation rating of 4 / 10 to CHROMADEX CORP (CDXC). This can be considered as Fairly Valued.
Can you provide the profitability details for CHROMADEX CORP?
CHROMADEX CORP (CDXC) has a profitability rating of 6 / 10.
What are the PE and PB ratios of CHROMADEX CORP (CDXC) stock?
The Price/Earnings (PE) ratio for CHROMADEX CORP (CDXC) is 78.7 and the Price/Book (PB) ratio is 13.27.
How financially healthy is CHROMADEX CORP?
The financial health rating of CHROMADEX CORP (CDXC) is 8 / 10.